Critical Pharmaceuticals Limited Secures £1.5M from Wellcome Trust to Develop hGH Nasal Spray  
10/14/2009 9:53:23 AM

NOTTINGHAM, England--(BUSINESS WIRE)--Critical Pharmaceuticals, the speciality pharmaceuticals company, today announced that it had secured a £1.5m translation award from the Wellcome Trust to develop a nasal spray of Human Growth Hormone (hGH) using its proprietary CriticalSorb technology as an alternative to injection. hGH, a leading biological drug for the treatment of growth disorders had global sales of $2.8bn in 2007.